IP Library › Granted Patent US 12,220,577
Granted Patent B2
US 12,220,577 · App. 17/365,244 · Granted Feb 11, 2025

Device for the transcutaneous electrical stimulation of the trigeminal nerve

Inventors: Pierre-Yves Muller (Collonge-Bellerive, CH); Pierre Rigaux (Liege, BE)
Assignee: Cefaly Technology SPRL
A61N1/36021A61N1/0456A61N1/0492A61N1/36025A61N1/3603A61N1/36034
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,220,577
App. No.
17/365,244
Granted
Feb 11, 2025
Kind
B2
Abstract

A device for the transcutaneous electrical stimulation of the trigeminal nerve is provided. The device has an elongated symmetrical support with at least one electrode pair, and the support can be applied on a person's forehead in the supraorbital region to cover the afferent paths of the supratrochlear and supraorbital nerves of the ophthalmic branch of the trigeminal nerve. Each electrode pair contacts a self-adhesive conductive gel that at least partially covers one surface of the support for attaching the support to the forehead to be applied to two lateral zones with the exception of an insulating central zone. Each lateral zone has one electrode of the electrode pair, an electric circuit for supplying to the electrode pair electric pulses that have a predefined intensity, and a measurement means for measuring the intensity of the supplied pulses that is connected to the electric circuit.

Claims (48)

1. A device for applying transcutaneous electrical stimulation to a patient, comprising:

an elongate support configured to be coupled to a forehead of the patient, the elongate support comprising a support surface comprising a first lateral zone, a second lateral zone, and a central zone therebetween, wherein the first lateral zone has a first lateral end opposite the central zone, and the second lateral zone has a second lateral end opposite the central zone;

a first electrode coupled to the first lateral zone and a second electrode coupled to the second lateral zone, the first electrode and the second electrode configured to stimulate a trigeminal nerve of the patient;

a conductive gel applied to between about 50% and about 80% of the support surface, wherein the first lateral end, the second lateral end, and the central zone are devoid of the conductive gel; and

a signal generator configured to supply pulses to the first electrode and the second electrode,

wherein the support is configured to removably couple to the signal generator and the support comprises at least two magnetizable metal connectors on a surface of the support facing away from the conductive gel, the at least two magnetizable metal connectors configured to removably couple to at least one magnet coupled to the signal generator.

2. The device of claim 1 , wherein the first lateral end and the second lateral end comprise up to about 20% of the elongate support.

3. The device of claim 1 , wherein each of the first lateral zone and the second lateral zone tapers from the central zone to the respective lateral end.

4. The device of claim 1 , wherein the conductive gel contacts the first electrode and the second electrode.

5. The device of claim 1 , wherein the pulses have an intensity between about 1 mA and about 35 mA.

6. The device of claim 1 , wherein the pulses have a duration of between about 150 microseconds and about 450 microseconds with a maximum increase in intensity of up to about 20 mA at a rate of less than or equal to about 40 microamperes per second and with a step up in intensity not exceeding about 50 microamperes.

7. The device of claim 1 , wherein the support is configured to cover an afferent path of a supratrochlear nerve and an afferent path of a supraorbital nerve of an ophthalmic branch of the trigeminal nerve.

8. The device of claim 7 , wherein the electrodes are configured for transcutaneous electrical stimulation of the trigeminal nerve.

9. The device of claim 1 , wherein the at least two magnetizable metal connectors are arranged along a longitudinal direction of the elongate support.

10. The device of claim 1 , wherein the at least two magnetizable metal connectors comprise a first magnetizable metal connector on the first lateral zone and a second magnetizable metal connector on the second lateral zone.

11. The device of claim 1 , wherein the at least two magnetizable metal connectors have a circular shape.

12. The device of claim 1 , wherein the central zone comprises a pin connector configured to removably couple to the signal generator.

13. The device of claim 1 , wherein the signal generator is configured to contact the first electrode and the second electrode when coupled to the support.

14. The device of claim 1 , wherein the support comprises a length of between about 70 mm and about 115 mm.

15. The device of claim 1 , wherein the central zone comprises a height of between about 15 mm and about 50 mm.

16. The device of claim 1 , wherein the first lateral end and the second lateral end each comprise a height of between about 5 mm and about 20 mm.

17. A method of treating a patient, comprising:

applying transcutaneous electrical stimulation to an afferent path of a supratrochlear nerve and an afferent path of a supraorbital nerve of an ophthalmic branch of a trigeminal nerve of the patient using pulses supplied to a stimulation device comprising an elongate support, wherein the elongate support comprises a support surface comprising a first lateral zone, a second lateral zone, and a central zone therebetween, wherein the first lateral zone has a first lateral end opposite the central zone and the second lateral zone has a second lateral end opposite the central zone, a first electrode coupled to the first lateral zone, a second electrode coupled to the second lateral zone, a conductive gel applied to between about 50% and about 80% of the support surface, wherein the first lateral end, the second lateral end, and the central zone are devoid of the conductive gel, and a signal generator supplying the pulses to the first electrode and the second electrode, wherein the support is removably coupled to the signal generator and the support comprises at least two magnetizable metal connectors on a surface of the support facing away from the conductive gel, the at least two magnetizable metal connectors removably coupled to at least one magnet coupled to the signal generator.

18. The method of claim 17 further comprising:

adhering the stimulation device to a forehead of the patient.

19. The method of claim 18 further comprising removing the stimulation device from the patient by the elongate support without touching the conductive gel.

20. The method of claim 17 further comprising measuring a number of treatment sessions using the stimulation device, a maximum pulse intensity for each of the treatment session, a maximum pulse intensity used throughout all the treatment sessions, and a start time and stop time for each of the treatment sessions.

21. The method of claim 17 , wherein the transcutaneous electrical stimulation is for treatment of one or more of migraine, tension, headaches, cluster headaches, hemicrania continua, Semi unilateral neuralgiform non conjunctival tearing (SUCNT), chronic paroxystic hemicranias, trigeminal neuralgia, facial nerve disturbances, fibromyalgia, chronic pain, depression, cyclothymia, post-traumatic stress syndrome, post-concussion syndrome, coma, anxiety, tremor, aphasia, obsessive compulsive disorder, insomnia, sleep disorders, sleep apnea syndrome, hypersomnia, epilepsy, drop attacks, attention deficit hyperactivity disorder, Parkinson's disease, Alzheimer's disease, multiple sclerosis, stroke, and Cerebellar syndrome.

22. A device for applying transcutaneous electrical stimulation to a patient, comprising:

an elongate support configured to be coupled to a forehead of the patient, the elongate support comprising a support surface comprising a first lateral zone, a second lateral zone, and a central zone therebetween, wherein the first lateral zone has a first lateral end opposite the central zone, and the second lateral zone has a second lateral end opposite the central zone;

a first electrode coupled to the first lateral zone and a second electrode coupled to the second lateral zone, the first electrode and the second electrode configured to stimulate a trigeminal nerve of the patient;

a conductive gel applied to between about 50% and about 80% of the support surface, wherein the first lateral end, the second lateral end, and the central zone are devoid of the conductive gel; and

a signal generator configured to supply pulses to the first electrode and the second electrode having a duration of between about 150 microseconds and about 450 microseconds with a maximum increase in intensity of up to about 20 mA at a rate of less than or equal to about 40 microamperes per second and with a step up in intensity not exceeding about 50 microamperes.

23. The device of claim 22 , wherein the first lateral end and the second lateral end comprise up to about 20% of the elongate support.

24. The device of claim 22 , wherein each of the first lateral zone and the second lateral zone tapers from the central zone to the respective lateral end.

25. The device of claim 22 , wherein the conductive gel contacts the first electrode and the second electrode.

26. The device of claim 22 , wherein the pulses have an intensity between about 1 mA and about 35 mA.

27. The device of claim 22 , wherein the pulses have a duration of between about 150 microseconds and about 450 microseconds with a maximum increase in intensity of up to about 20 mA at a rate of less than or equal to about 40 microamperes per second and with a step up in intensity not exceeding about 50 microamperes.

28. The device of claim 22 , wherein the support is configured to cover an afferent path of a supratrochlear nerve and an afferent path of a supraorbital nerve of an ophthalmic branch of the trigeminal nerve.

29. The device of claim 28 , wherein the electrodes are configured for transcutaneous electrical stimulation of the trigeminal nerve.

30. The device of claim 22 , wherein the central zone comprises a pin connector configured to removably couple to the signal generator.

31. The device of claim 22 , wherein the signal generator is configured to contact the first electrode and the second electrode when coupled to the support.

32. The device of claim 22 , wherein the support comprises a length of between about 70 mm and about 115 mm.

33. The device of claim 22 , wherein the central zone comprises a height of between about 15 mm and about 50 mm.

34. The device of claim 22 , wherein the first lateral end and the second lateral end each comprise a height of between about 5 mm and about 20 mm.

35. A method of treating a patient, comprising:

applying transcutaneous electrical stimulation to an afferent path of a supratrochlear nerve and an afferent path of a supraorbital nerve of an ophthalmic branch of a trigeminal nerve of the patient using pulses supplied to a stimulation device comprising an elongate support, wherein the elongate support comprises a support surface comprising a first lateral zone, a second lateral zone, and a central zone therebetween, wherein the first lateral zone has a first lateral end opposite the central zone and the second lateral zone has a second lateral end opposite the central zone, a first electrode coupled to the first lateral zone, a second electrode coupled to the second lateral zone, and a conductive gel applied to between about 50% and about 80% of the support surface, wherein the first lateral end, the second lateral end, and the central zone are devoid of the conductive gel; and

measuring a number of treatment sessions using the stimulation device, a maximum pulse intensity for each of the treatment session, a maximum pulse intensity used throughout all the treatment sessions, and a start time and stop time for each of the treatment sessions.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2025
From: MULLER, PIERRE-YVES; RIGAUX, PIERRE
To: CEFALY TECHNOLOGY SPRL
Reel/Frame 070367/0537 →
SECURITY INTEREST Recorded Feb 21, 2025
From: CEFALY TECHNOLOGY SRL
To: CRG SERVICING LLC
Reel/Frame 070295/0542 →
Continuity (3)
Continuation 16803481 · Feb 27, 2020
Division 15558386
Related Publication 20220096833A1 · Mar 31, 2022
References Cited (274)
US 2782786A · Krasno · 1957 [cited by applicant]
US 3620219A · Barker · 1971 [cited by applicant]
US 3709228A · Barker · 1973 [cited by applicant]
US 3746004A · Elson · 1973 [cited by applicant]
US 3971387A · Mantell · 1976 [cited by applicant]
US 3998213A · Price · 1976 [cited by applicant]
US 4112941A · Larimore · 1978 [cited by applicant]
US 4165750A · Aleev · 1979 [cited by applicant]
US 4209234A · McCooeye · 1980 [cited by applicant]
US 4288222A · Kling · 1981 [cited by applicant]
US 4509521A · Barry · 1985 [cited by applicant]
US 4537198A · Corbett · 1985 [cited by applicant]
US 4816964A · Weiss · 1989 [cited by applicant]
US 4841954A · Kalsi · 1989 [cited by applicant]
US 4957480A · MoreninQs · 1990 [cited by applicant]
US 5402780A · Faasse, Jr. · 1995 [cited by examiner]
US 5496363A · BurQio · 1996 [cited by applicant]
US 5527357A · Springer, Jr. · 1996 [cited by applicant]
US 5540734A · Zabara · 1996 [cited by applicant]
US 5726916A · Smyth · 1998 [cited by applicant]
US 5785040A · Axelgaard · 1998 [cited by applicant]
US 5913836A · Groux · 1999 [cited by applicant]
US 6077237A · Campbell · 2000 [cited by applicant]
US 6198955B1 · Axelgaard · 2001 [cited by applicant]
US 6233472B1 · Bennett · 2001 [cited by applicant]
US 6563424B1 · Kaario · 2003 [cited by applicant]
US 6654626B2 · Devlin · 2003 [cited by applicant]
US 6735475B1 · Whitehurst · 2004 [cited by applicant]
US 6954668B1 · Cuozzo · 2005 [cited by applicant]
US 7949403B2 · Palermo · 2011 [cited by applicant]
US 8380315B2 · DeGiorgio · 2013 [cited by applicant]
US 8428734B2 · Rigaux · 2013 [cited by applicant]
US 8583238B1 · Heldman et al. · 2013 [cited by applicant]
US 8615309B2 · Craig · 2013 [cited by applicant]
US 8688220B2 · Degiorgio · 2014 [cited by applicant]
US 8700164B2 · Degiorgio · 2014 [cited by applicant]
US 8702584B2 · Rigaux · 2014 [cited by applicant]
US 8718778B2 · Bikson · 2014 [cited by applicant]
US 8805548B2 · Mignolet · 2014 [cited by applicant]
US 8914123B2 · Rigaux · 2014 [cited by applicant]
US 9042991B2 · Reed · 2015 [cited by applicant]
US 9108041B2 · Craig · 2015 [cited by applicant]
US 9233244B2 · Pal · 2016 [cited by applicant]
US 9238139B2 · Degiorgio · 2016 [cited by applicant]
US 9364674B2 · Cook · 2016 [cited by applicant]
US 9433774B2 · Dar · 2016 [cited by applicant]
US 9504827B2 · Degiorgio · 2016 [cited by applicant]
US 9675794B2 · Miller · 2017 [cited by applicant]
US 9682236B2 · Degiorgio · 2017 [cited by applicant]
US 9731127B2 · Kealey · 2017 [cited by applicant]
US D797298S · Muller · 2017 [cited by applicant]
US 9782584B2 · Cartledge · 2017 [cited by applicant]
US 9872979B2 · Dar · 2018 [cited by applicant]
US 9956405B2 · Goldwasser · 2018 [cited by applicant]
US 9987486B2 · Rigaux · 2018 [cited by applicant]
US 10016601B2 · Cook · 2018 [cited by applicant]
US 10058704B2 · Degiorgio · 2018 [cited by applicant]
US 10195455B2 · Stubbernan · 2019 [cited by applicant]
US 10322283B2 · Degiorgio · 2019 [cited by applicant]
US 10376695B2 · Errico · 2019 [cited by applicant]
US 10376965B2 · Hengsberger · 2019 [cited by applicant]
US 10485970B2 · Gerber · 2019 [cited by applicant]
US 10525254B2 · Miller · 2020 [cited by applicant]
US 10537729B2 · Cook · 2020 [cited by applicant]
US 10576279B2 · Muller · 2020 [cited by applicant]
US 10773080B2 · Rigaux · 2020 [cited by applicant]
US 10814131B2 · Goldwasser et al. · 2020 [cited by applicant]
US 10864371B2 · Shimada · 2020 [cited by applicant]
US 11052251B2 · Muller · 2021 [cited by applicant]
US 11065444B2 · Errico · 2021 [cited by applicant]
US 11433234B2 · Rigaux · 2022 [cited by applicant]
US 20020161416A1 · Huang · 2002 [cited by applicant]
US 20030045922A1 · Northrop · 2003 [cited by applicant]
US 20040039328A1 · Henley · 2004 [cited by applicant]
US 20040073129A1 · Caldwel · 2004 [cited by applicant]
US 20040260359A1 · Osrud · 2004 [cited by applicant]
US 20050038486A1 · Mulholland · 2005 [cited by applicant]
US 20050187497A1 · Nguyen · 2005 [cited by applicant]
US 20060077340A1 · Curiel · 2006 [cited by applicant]
US 20060136009A1 · Staffel · 2006 [cited by applicant]
US 20060154078A1 · Watanabe · 2006 [cited by applicant]
US 20060293608A1 · Rothman · 2006 [cited by applicant]
US 20070233194A1 · Craig · 2007 [cited by applicant]
US 20070276449A1 · Gunter · 2007 [cited by applicant]
US 20080051764A1 · Dent · 2008 [cited by applicant]
US 20090082831A1 · Paul · 2009 [cited by applicant]
US 20090088810A1 · Covey et al. · 2009 [cited by applicant]
US 20090105576A1 · Do · 2009 [cited by applicant]
US 20090112282A1 · Kast · 2009 [cited by applicant]
US 20100030299A1 · Covalin · 2010 [cited by applicant]
US 20100042180A1 · Mueller et al. · 2010 [cited by applicant]
US 20100113959A1 · Pascual-Leone · 2010 [cited by applicant]
US 20100274327A1 · Carroll et al. · 2010 [cited by applicant]
US 20100306902A1 · Bourque · 2010 [cited by applicant]
US 20110282129A1 · Rigaux · 2011 [cited by examiner]
US 20110319975A1 · Ho · 2011 [cited by applicant]
US 20130296967A1 · Skaribas et al. · 2013 [cited by applicant]
US 20140031895A1 · Rahimi et al. · 2014 [cited by applicant]
US 20140081369A1 · Sosa et al. · 2014 [cited by applicant]
US 20140188200A1 · DeGiorgio · 2014 [cited by applicant]
US 20140228906A1 · DeGiorgio et al. · 2014 [cited by applicant]
US 20140324146A1 · Muller · 2014 [cited by applicant]
US 20150046175A1 · Jorgenson et al. · 2015 [cited by applicant]
US 20150066104A1 · Wingeier · 2015 [cited by applicant]
US 20150335888A1 · Demers · 2015 [cited by applicant]
US 20160022987A1 · Zschaeck · 2016 [cited by applicant]
US 20170165485A1 · Sullivan · 2017 [cited by applicant]
US 20170281940A1 · de Oliveira · 2017 [cited by applicant]
US 20180014740A1 · Hayakawa · 2018 [cited by applicant]
US 20190201684A1 · Williams et al. · 2019 [cited by applicant]
US 20200046970A1 · Gerber · 2020 [cited by applicant]
US 20200054887A1 · Levin · 2020 [cited by applicant]
US 20200147340A1 · Tyler · 2020 [cited by applicant]
US 20200179689A1 · Rigaux · 2020 [cited by applicant]
US 20210370047A1 · Rigaux · 2021 [cited by applicant]
US 20230108691A1 · Rigaux · 2023 [cited by applicant]
US 20240024661A1 · Trainor-McDermott et al. · 2024 [cited by applicant]
CA 2082092A1 · 1993 [cited by applicant]
CA 915928A · 2014 [cited by applicant]
CN 2531817Y · 2003 [cited by applicant]
CN 101072602A · 2007 [cited by applicant]
CN 103269746B · 2010 [cited by applicant]
CN 102698360A · 2012 [cited by applicant]
CN 206239894U · 2017 [cited by applicant]
DE 102007021960A1 · 2008 [cited by applicant]
EP 2646109B1 · 2013 [cited by applicant]
EP 3639883A1 · 2020 [cited by applicant]
JP H9294815A · 1997 [cited by applicant]
JP 2008516696A · 2008 [cited by applicant]
JP 009531154A5 · 2009 [cited by applicant]
JP 2011509743A5 · 2011 [cited by applicant]
JP 2012509121A · 2012 [cited by applicant]
JP 2013506534A · 2013 [cited by applicant]
JP 2017519549A · 2017 [cited by applicant]
JP 2018510047A · 2018 [cited by applicant]
KR 1020140037803 · 2014 [cited by applicant]
KR 20140098782A · 2014 [cited by applicant]
KR 101473443B1 · 2014 [cited by applicant]
WO WO0045701A1 · 2000 [cited by applicant]
WO WO0071075A1 · 2000 [cited by applicant]
WO WO0103638A1 · 2001 [cited by applicant]
WO WO2006051370A1 · 2006 [cited by applicant]
WO WO2006063417A1 · 2006 [cited by applicant]
WO WO2008004204A1 · 2008 [cited by applicant]
WO WO2008005478A2 · 2008 [cited by applicant]
WO WO09091578A1 · 2009 [cited by applicant]
WO WO2009137683A2 · 2009 [cited by applicant]
WO WO2010057998A1 · 2010 [cited by applicant]
WO WO2011044173A1 · 2011 [cited by applicant]
WO WO2011151742A1 · 2011 [cited by applicant]
WO WO2012079778A1 · 2012 [cited by applicant]
WO WO2013022840A1 · 2013 [cited by applicant]
WO WO2013104552A1 · 2013 [cited by applicant]
WO WO2013152316A1 · 2013 [cited by applicant]
WO WO2014052981A1 · 2014 [cited by examiner]
WO WO2014141213A1 · 2014 [cited by applicant]
WO WO2016044659A1 · 2016 [cited by applicant]
WO WO2016106182A1 · 2016 [cited by applicant]
WO WO2016111974A1 · 2016 [cited by applicant]
WO WO2016155773A1 · 2016 [cited by applicant]
WO WO2017130133A1 · 2017 [cited by applicant]
WO WO2017178946A1 · 2017 [cited by applicant]
WO WO2016042278A1 · 2018 [cited by applicant]
WO WO2018210949A1 · 2018 [cited by applicant]
WO WO2020079218A1 · 2020 [cited by applicant]
Ahmed et al., Use of the percutaneous electrical nerve stimulation (PENS) in the short-term management of headache, Headache, 2000, pp. 311-315, vol. 40. [cited by applicant]
Allais et al., Non-pharmacological approaches to chronic headaches: transcutaneous electricalnerve stimulation, lasertherapy and acupuncture in transformed migraine treatment, Neurol Sci, 2003, pp. SI38-SI42, vol. 24. [cited by applicant]
Alon, Chapter 3—Principles of Electrical Stimulation, Clinical Electrotherapy Appleton & Lange, 1987, pp. 29-47. [cited by applicant]
Angelakis et al., Transcranial Direct Current Stimulation Effects in Disorders of Consciousness, Archives of Physical Medicine and Rehabilitation, 2014, pp. 283-289, vol. 95. [cited by applicant]
Anonymous. Migraine, International Classification of Headache Disorders, 3rd edition, 2013, 3 pages. [cited by applicant]
Bigland-Ritchie, EMG and Fatigue of Human Voluntary and Stimulated Contractions, Human Muscle Fatigue: Physiological Mechanisms, Pitman Medical London 1981 (Ciba Foundation Symposium 82), pp. 130-156. [cited by applicant]
Burton, Scaffolding to build a rational vaccine design strategy, PNAS, Oct. 19, 2010, pp. 17859-17860, vol. 107, No. 42. [cited by applicant]
Cady et al., A Randomized, Double-Blind, Placebo-Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of Acute Migraine (The TARGET Study), Headache, 2015, pp. 88-100, vol. … [cited by applicant]
Cameron et al., Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-analysis, Headache, 2015, pp. 221-235, vol. 4. [cited by applicant]
Chou, et al., Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial, Cephalalgia, 2019, pp. 3-14, vol. 39, No. 1. [cited by applicant]
Chou, et al., External Trigeminal Nerve Stimulation for the Acute Treatment of Migraine: Open-Label Trial on Safety and Efficacy, Neuromodulation, Oct. 2017. 2017, pp. 678-683, vol. 20, No. 7. [cited by applicant]
Clark et al., Long-Term Pain Reduction Does Not Imply Improved functional Outcome inPatients Treated with Combined Supraorbital and Occipital Nerve Stimulation for Chronic Migraine, Nueomodulation: Technology at the Neu… [cited by applicant]
Cunningham, et al., Comparison of a Structural and a Functional Epitope, J. Mol. Biol., 1993, pp. 554-563, vol. 234. [cited by applicant]
Difore, et al., Transcutaneous supraorbital neurostimulation for the prevention of chronicmigraine: a prospective, open-label preliminary trial, Neurological Sciences, 2017, pp. 201-206, vol. 38, No. S1. [cited by applicant]
European Patent Office, International Preliminary Report on Patentability for PCT/EP2011/054072, Jan. 16, 2013, 6 pages. [cited by applicant]
European Patent Office, International Preliminary Report on Patentability for PCT/EP2015/056889, Jun. 27, 2017, 14 pages. [cited by applicant]
European Patent Office, International Preliminary Report on Patentability for PCT/EP2018/062779, Jul. 22, 2019, 14 pages. [cited by applicant]
European Patent Office, International Preliminary Report on Patentability for PCT/IB2017/054905, Nov. 5, 2018, 17 pages. [cited by applicant]
European Patent Office, International Search Report and Written Opinion for for PCT/EP2011/054072, Jul. 27, 2011, 13 pages. [cited by applicant]
European Patent Office, International Search Report and Written Opinion for for PCT/EP2018/062779, Jun. 15, 2018, 9 pages. [cited by applicant]
European Patent Office, International Search Report and Written Opinion for for PCT/EP2019/078355, Jan. 30, 2020, 12 pages. [cited by applicant]
European Patent Office, International Search Report and Written Opinion for for PCT/IB2017/054905, Nov. 7, 2017, 13 pages. [cited by applicant]
Farina et al., Headache and cervical spine disorders: Classification and treatment with transcutaneous electrical nerve stimulation, 1986, 3 pages. [cited by applicant]
Farkkila et al., Efficacy and Tolerability of Lasmiditan, An Oral 5-HT1F Receptor Agonist, forthe Acute Irreatment of Migraine: A Phase 2 Randomised, Placebo-Controlled, Parallel-Group, Dose-Ranging Study, The ancet Neu… [cited by applicant]
Gaul et al., Non-Invasive Vagus Nerve Stimulation for PREVention and Acute Treatment ofChronic Cluster Headache PREVA): A Randomised Controlled Study, Cephalalgia, Sep. 21, 2015, pp. 534-546, vol. 36, No. 6. [cited by applicant]
Giani et al., P062. Sensory Modalities During Dreams in Migraine, The Journal of Headache and Pain, Sep. 28, 2015, 2 pages, vol. 16. [cited by applicant]
Goldstein et al., A Sumatriptan Iontophoretic Transdermal System for the Acute Treatment of Migraine, Headache, 2012, pp. 1402-1410, vol. 52, No. 9. [cited by applicant]
Gori, et al., Peptides for immunological purposes: design, strategies and applications, Amino Acids, 2013, pp. 257-268, vol. 45. [cited by applicant]
He, et al., Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding, Nature, Scientific Reports, Aug. 4, 2015, 16 pages. [cited by applicant]
Huang, et al., Mimotope-Based Prediction of B-Cell Epitopes, Immunoinformatics, Methods in Molecular Biology, Chapter 13, pp. 237-243, vol. 1184. [cited by applicant]
European Patent Office, International Preliminary Report on Patentability for PCT/EP2019/078355, Apr. 14, 2021, 8 pages. [cited by applicant]
European Patent Office, English translation of International Preliminary Report on Patentability for PCT/BE2005/000135, Jun. 14, 2007, 9 pages. [cited by applicant]
European Patent Office, English translation of International Search Report for PCT/EP2013/050047, Jul. 13, 2014, 3 pages. [cited by applicant]
European Patent Office, English translation of Preliminary Report on Patentability for PCT/EP2013/050047, Jul. 13, 2014, 3 pages. [cited by applicant]
Jasper et al., Implanted Occipital Nerve Stimulators, Pain Physician, 2008, 14 pages. [cited by applicant]
Jones et al., Excitation Frequency and Muscle Fatigue: Mechanical Responses during Voluntary and Stimulated Contractions, Experimental Neurology 64, 1979, pp. 401-413. [cited by applicant]
Jones, High and Low-Frequency Fatigue Revisited, Acta Physiol. Scand. 156, 1996, pp. 265-270. [cited by applicant]
Jones, Muscle Fatigue due to Changes Beyond the Neuromuscular Junction, Human MuscleFatigue: Physiological Mechanisms, Pitman Medical London, 1981 (Ciba Foundation Symposium 82), pp. 178-196. [cited by applicant]
Kelley, et al., Thermodynamic Analysis of an Antibody Functional Epitope, Biochemistry, 1993, pp. 6828-6835, vol. 32. [cited by applicant]
Kozminsky, Transcutaneous Supraorbital Nerve Stimulation as a Rescue Therapy, Headache, Jun. 1, 2014, p. 12, vol. 54. [cited by applicant]
Kuruvilla, et al., Acute treatment of migraine with external trigeminal nerve stimulation: A pilot trial, Cephalalgia Reports, 2019, pp. 1-6, vol. 2. [cited by applicant]
Lauristen, et al., Rationale for electrical parameter determination in external trigeminal nerve stimulation (eTNS) for migraine: A narrative review, Cephalalgia, 2019, pp. 750-760, vol. 39, No. 6. [cited by applicant]
Liljeroos, et al., Structural and Computational Biology in the Design of Immunogenic Vaccine Antigens, Journal of Immunology Research, Article ID 156241, 2015, 17 pages. [cited by applicant]
Luo, et al., Targeting Melanoma Cells with Human High Molecular Weight-Melanoma AssociatedAntigen-Specific Antibodies Elicited by a Peptide Mimotope: Functional Effects, The Journal of Immunology, 2006, pp. 6046-6054. [cited by applicant]
Levine et al., Relaxation of Spasticity by Electrical Stimulation of Antagonist Muscles, Arch. Phys. Med., 1952, pp. 668-673, vol. 33. [cited by applicant]
Lipton et al., Single-Pulse Transcranial Magnetic Stimulation for Acute Treatment of Migrainewith Aura: A Randomised, Double-Blind, Parallel-Group, Sham-Controlled Trial, The Lancet Neurology, 2010, pp. 373-380, vol. 9,… [cited by applicant]
Magis et al., Cerebral metabolism before and after external trigeminal nerve stimulation in episodic migraine, Cephalalgia, 2017, pp. 881-891, vol. 37, No. 9. [cited by applicant]
Magis et al., Occipital Nerve Stimulation for Drug-Resistant Chronic Cluster Headache: A Prospective Pilot Study, 2007, 8 pages. [cited by applicant]
Magis et al., Safety and Patients' Satisfaction of Transcutaneous Supraorbital NeuroStimulation(tSNS) with the Cefaly Device in Headache Treatment: A Survey of 2,313 headache sufferers in the General Population, The Jou… [cited by applicant]
McLellan, et al., Design and Characterization of Epitope-Scaffold Immunogens That Presentthe Motavizumab Epitope from Respiratory Syncytial Virus, Journal of Molecular Biology, 2011, pp. 853-866, vol. 409. [cited by applicant]
Melzack et al., Pain mechanisms: A new theory, Science, 1965, pp. 971-979, vol. 150. [cited by applicant]
Ohtaki, et al., Structure-Based Peptide Mimicry of Tumor-Associated Antigens, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2013, 5 pages, vol. 32, No. 1. [cited by applicant]
Pantophlet, et al., Immunofocusing: antigen engineering to promote the induction of HIV-neutralizing antibodies, Trends in Molecular Medicine, Nov. 2003, pp. 468-473, vol. 9 No. 11. [cited by applicant]
Penning, et al., A survey on migraine attack treatment with the CEFALY® device in regular users, Acta Neurologica Belgica, 2017, pp. 547-549, vol. 117, No. 2. [cited by applicant]
Pierce, et al., Structure-Based Design of Hepatitis C Virus Vaccines That Elicit NeutralizingAntibody Responses to a Conserved Epitope, Journal of Virology, Oct. 2017, 16 pages, vol. 91, No. 20. [cited by applicant]
Piquet et al., Supraorbital transcutaneous neurostimulation has sedative effects in healthy subjects, BioMed Central, BMC Neurology Oct. 28, 2011, 8 pages, vol. 11, No. 135. [cited by applicant]
Reed et al., Combined Occipital and Supraorbital Neurostimulation for the Treatment of Chronic Migraine Headaches: Initial Experience, Cephalalgia, 2010, pp. 260-271, vol. 30, No. 3. [cited by applicant]
Riederer, et al., Transcutaneous Supraorbilal Nerve Stimulation {I-SNS) with the Cefaly Devicefor Migraine Prevention: A Review of the Available Data, Pain and Therapy, Oct. 14, 2015, pp. 135-147, vol. 4, No. 2. [cited by applicant]
Riemer, Mimotope vaccines: Epitope mimics induce anti-cancer antibodies, Immunol Letters, Oct. 31, 2007, 9 pages, vol. 113, No. 1. [cited by applicant]
Robinson et al., Clinical Electrophysiology, Instrumentation for Neuromuscular electrical stimulation, Lippincott Williams & Wilkins, 1989, 8 pages. [cited by applicant]
Ru, et al., MimoDB: a New Repository for Mimotope Data Derived from Phage Display Technology, Molecules, 2010, pp. 8279-8288, vol. 15. [cited by applicant]
Russo et al., Functional Changes of the Perigenual Part of the Anterior Cingulate Cortex afterExternal Trigeminal Neurostimulation in Migraine Patients, Front Neurol., Jun. 2017, 9 pages, vol. 8, No. 282. [cited by applicant]
Russo et al., Transcutaneous Supraorbital Neurostimulation in “de nova” Patients With Migraine Without Aura: the first Italian Experience, The Journal of Headache and Pain, 2015, 7 pages, vol. 16, No. 69. [cited by applicant]
Saper et al., Occipital Nerve Stimulation for the Treatment of Intractable Chronic Migraine Headache: ONSTIM easibility Study, Cephalalgia, 2010, pp. 271-285, vol. 31, No. 3. [cited by applicant]
Schoenen et al., Efficacy and mode of action of external trigeminal neurostimulation in migraine, Expert Review of Neurotherapeutics, 2018, pp. 545-555, vol. 18, No. 7. [cited by applicant]
Schoenen et al., Migraine Prevention with a Supraorbital Transcutaneous Stimilator: A Randomized Controlled Trial, Neurology, Feb. 6, 2013, pp. 697-704, vol. 80, No. 8. [cited by applicant]
Schoenen et al., Stimulation of the Sphenopalatine Ganglion (SPG) for Cluster HeadacheTreatment. Pathway CH-I: Randomized, Sham-Controlled Study, Cephalalgia, 2013, pp. 816-830, vol. 33, No. 10. [cited by applicant]
Silberstein et al., Chronic Migraine Headache Prevention with Noninvasive Vagus Nerve Stimulation, American Academy of Neurology, Aug. 2, 2016, pp. 529-538. [cited by applicant]
Solomon et al., Treatment of headache by transcutaneous electrical stimulation, Headache, 1985, pp. 12-15, vol. 25. [cited by applicant]
Spierings et al., Randomized, Double-Blind, Placebocontrolled, Parallel-Group, Multi-CenterStudy of the Safety and Efficacy of Adam Zolmitriptan for the Acute Treatment of Migraine, Cephalalgia, 2018, pp. 215-222, vol. … [cited by applicant]
Straube et al., Treatment of Chronic Migraine with Transcutaneous Stimulation of the AuricularBranch of the Vagal Nerve (Auricular T-VNS): A Randomized, Monocentric Clinical Trial, The Journal of Headache and Pain, 2015… [cited by applicant]
The Diclofenac-K/Sumatriptan Migraine Study Group, Acute Treatment of MigraineAttacks: Efficacy and Safety of a Nonsteroidal Anti-inflammatory Drug, Diclofenac-potassium, in Comparison to Oral Sumatriptan and lacebo, Ce… [cited by applicant]
Tice, et al., Controversies in Migraine Management: A Technology Assessment Final Report Aug. 19, 2014, Completed by Institute for Clinical and Economic Review, Downloaded from: chrome- extension://efaidnbmnnnibpcajpcgl… [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action for U.S. Appl. No. 11/667,223, filed Jun. 11, 2009, 18 pages. [cited by applicant]
United States Patent and Trademark Office, Final Office Action for U.S. Appl. No. 11/667,223, filed Jun. 10, 2010, 10 pages. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action for U.S. Appl. No. 11/667,223, filed Feb. 17, 2011, 13 pages. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action for U.S. Appl. No. 11/667,223, filed Jul. 22, 2011, 10 pages. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action for U.S. Appl. No. 11/667,223, filed Feb. 14, 2012, 10 pages. [cited by applicant]
United States Patent and Trademark Office, Final Office Action for U.S. Appl. No. 11/667,223, filed Aug. 3, 2012, 13 pages. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action for U.S. Appl. No. 11/667,223, filed Apr. 30, 2013, 12 pages. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action for U.S. Appl. No. 11/667,223, filed Apr. 24, 2014, 13 pages. [cited by applicant]
United States Patent and Trademark Office, Final Office Action for U.S. Appl. No. 11/667,223, filed Nov. 21, 2013, 11 pages. [cited by applicant]
United States Patent and Trademark Office, Notice of Allowance for U.S. Appl. No. 11/667,223, filed Aug. 26, 2014, 7 pages. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action for U.S. Appl. No. 12/359,716, filed Sep. 13, 2011, 5 pages. [cited by applicant]
United States Patent and Trademark Office, Final Office Action for U.S. Appl. No. 12/359,716, filed Jul. 18, 2012, 6 pages. [cited by applicant]
United States Patent and Trademark Office, Notice of Allowance for U.S. Appl. No. 12/359,716, filed Jan. 2, 2013, 5 pages. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action for U.S. Appl. No. 13/101,495, filed Mar. 29, 2013, 5 pages. [cited by applicant]
United States Patent and Trademark Office, Final Office Action for U.S. Appl. No. 13/101,495, filed Sep. 30, 2013, 6 pages. [cited by applicant]
United States Patent and Trademark Office, Notice of Allowance for U.S. Appl. No. 13/101,495, filed Dec. 10, 2013, 7 pages. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action for U.S. Appl. No. 15/250,431, filed Nov. 22, 2017, 6 pages. [cited by applicant]
United States Patent and Trademark Office, Notice of Allowance for U.S. Appl. No. 15/250,431, filed Mar. 29, 2018, 6 pages. [cited by applicant]
United States Patent and Trademark Office, Restriction Requirment for U.S. Appl. No. 15/558,386, filed May 1, 2019, 7 pages. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action for U.S. Appl. No. 15/558,386, filed May 31, 2019, 9 pages. [cited by applicant]
United States Patent and Trademark Office, Notice of Allowance for U.S. Appl. No. 15/558,386, filed Oct. 30, 2019, 7 pages. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action for U.S. Appl. No. 15/980,220, filed Nov. 26, 2019. [cited by applicant]
United States Patent and Trademark Office, Notice of Allowance for U.S. Appl. No. 15/980,220, filed May 12, 2020, 5 pages. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action for U.S. Appl. No. 16/803,481, filed Nov. 12, 2020, 9 pages. [cited by applicant]
United States Patent and Trademark Office, Notice of Allowance for U.S. Appl. No. 16/803,481, filed Mar. 10, 2021, 8 pages. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action for U.S. Appl. No. 13/914,096, filed Dec. 16, 2013, 12 pages. [cited by applicant]
United States Patent and Trademark Office, Notice of Allowance for U.S. Appl. No. 13/914,096, filed Apr. 17, 2014, 10 pages. [cited by applicant]
United States Patent and Trademark Office, Non-Final Office Action for U.S. Appl. No. 14/328,396, filed Apr. 10, 2015, 7 pages. [cited by applicant]
Vikelis, et al., Clinical experience with transcutaneous supraorbital nerve stimulation in patientswith refractory migraine or with migraine and intolerance to topiramate: a prospective exploratory clinical study, BMC N… [cited by applicant]
Voss et al., A Phase Ilb Randomized, Double-blind, Placebo-controlled Trial of Ubrogepant for the Acute Irreatment of Migraine, Cephalalgia, 2016, pp. 887-898, vol. 36, No. 9. [cited by applicant]
Wal, Modulation of Spasticity: Prolonged Suppression of a Spinal Reflex by Electrical Stimulation, Science, Apr. 9, 1982, pp. 203-204, vol. 216. [cited by applicant]
Wall et al., Temporary abolition of pain in man, Science, Jan. 6, 1967, pp. 108-109. [cited by applicant]
Wikipedia, Mimotope, 2 pages. Retrieved from https://en.wikipedia.org/w/index.php?title=Mimotope&oldid=775942536. [cited by applicant]
Woolf et al., Antinociceptiv effect of peripheral segmental electrical stimulation in the rat, Pain, 1980, pp. 237-252, vol. 8. [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/EP2023/063527 dated Oct. 16, 2023, 19 pages. [cited by applicant]
European Search Report in EP App. No. 18201148, mailed Apr. 2, 2019, 6 pages. [cited by applicant]